Dear Editor,

Multiple myeloma (MM) is a disease characterized by the clonal expansion of malignant plasma cells in the marrow, leading to anemia, hypercalcemia, bone lesion, and renal dysfunction [1]. Immunoglobulin D (IgD) myeloma is a rare subtype of MM, accounting for approximately 1% to 2% of all MM patients [2]. It occurs at a young age, often accompanied with a high disease burden and short median survival (18–21 months) [3, 4]. Several studies have suggested that in patients with IgD subtype, the outcomes of those who have had undergone autologous stem cell transplantation (ASCT) were superior than those treated with chemotherapy alone [5, 6]. However, these have been debatable as other reports have displayed opposite results [7, 8].

In the last decade, novel agents such as proteasome inhibitor and immunomodulatory agents have been used to treat MM, which have resulted in a 50% improvement in the patients’ overall survival (OS: 44.8 vs. 29.9 months) [9]. However, given the rarity of IgD myeloma, studies on it remain rare. Knowledge about this subtype was mostly derived from few single-center case series. In China, there has been no report to fully elucidate on whether the results of survival outcomes for patients with IgD subtype from novel agents could be replicated in those with non-IgD subtypes. Here, we performed a retrospective analysis on 216 symptomatic MM patients, diagnosed from August 2006 to April 2018, at the Jinling Hospital (Nanjing, Jiangsu, China). The patient cohort comprised of 13 with IgD subtype and 203 with non-IgD subtypes. Three new drugs, bortezomib, thalidomide, and lenalidomide, were used as induction therapy choice, based on which we investigated their clinical manifestations, treatment responses, and outcomes. In this study cohort, 1 patient with IgD subtype and 11 with non-IgD subtypes underwent ASCT.

First, we compared the clinical features between the IgD and non-IgD subtypes (Table 1). The median age of onset for the IgD subtype was 52 years, which was younger than that of the non-IgD subtypes (60 years, \( P = 0.028 \)). The rate of \( \lambda \) light chain was significantly higher in patients with the IgD subtype than in those with non-IgD subtypes (92.3% vs. 48.8%, \( P = 0.006 \)). Moreover, as compared with non-IgD subtypes, patients with IgD subtype presented more often with significant renal dysfunction (creatinine > 2 mg/L, \( P < 0.001 \)) and amyloid light-chain (AL) amyloidosis (\( P = 0.001 \)) and had higher frequencies of critical clinical features such as International staging system (ISS)-III disease (\( P = 0.002 \)), severe anemia (Hemoglobin < 90 g/L, \( P = 0.011 \)), high \( \beta_2 \) microglobulin (\( \beta_2 \)M) concentration (\( P = 0.001 \)), and elevated lactate dehydrogenase (LDH > 250 U/L, \( P = 0.002 \)). However, there were no significant differences in sex, platelet counts, bone lesion, hypercalcemia, urine protein, induction therapy, and extramedullary infiltration between IgD and non-IgD subtypes.

Based on the data from Table 2, we found that 30.8% (4/13) of patients with IgD subtype presented with significant abnormalities in serum-free light chain (sFLC) ratio (< 0.01 or > 100) at baseline, compared with 7.5% (13/173) for the non-IgD subtypes (\( P = 0.021 \)). Moreover, about half of those (46.2%) with IgD subtype showed an obvious increase in sFLC ratio abnormalities when relapsed (\( P < 0.001 \)).

Of the 216 MM patients, 198 (91.7%) were subjected to cytogenetic abnormality testing (Table 3). 1q21 amplification was discovered in 9 patients with IgD subtype, which was higher than that in patients with non-IgD subtypes (75.0% vs. 40.3%, \( P = 0.018 \)). The rate of t (14;16)
was also significantly higher in patients with IgD subtype than those with the non-IgD subtypes (17.0% vs. 1.6%, \( P = 0.023 \)). However, no significant differences in other cytogenetic abnormalities such as 13 deletions, t (4;14), t (11;14), p53 deletion, and hyperdiploid between the IgD and non-IgD subtypes were found.
Second, we analyzed the treatment response between the IgD and non-IgD subtypes and have listed their detailed information regarding the treatment and survival of the patients with IgD subtype in Table 4. By the end of follow-up on August 31, 2018, 71 deaths were recorded of whom 9 cases (69.2%) were from patients having the IgD subtype. The overall response rate of the entire cohort was 93.5% (202/216). Response of induction therapy for the IgD subtype was similar to that of the non-IgD subtypes ($P=0.847$, Table 1). However, the median duration of response in patients with IgD subtype was 10 months, which was significantly shorter than that of patients with non-IgD subtypes (23.6 months, $P=0.002$) (Fig. 1a). The median follow-up of the 216 patients was 32.4 months (range 0.96–147 months). In patients with IgD subtype, the median progression-free survival (PFS) was 10.0 months and the median OS was 22.9 months, compared with 27.9 months ($P=0.003$; Fig. 1b) and 81.7 months ($P<0.001$; Fig. 1c) for patients bearing the non-IgD subtypes.

Lastly, we analyzed the other risk factors that might have affected the prognoses of the investigated MM patients (Additional file 1: Table S1). Univariate analyses showed that, besides the IgD subtype, patients with high β2M level, elevated LDH level, having extramedullary infiltration, ISS stage III, 13q deletion, 1q21 amplification, IGH rearrangement, and abnormal sFLC ratio had shorter OS compared with their counterparts (Additional file 2: Figure S1). Multivariate analyses showed that IgD subtype was an independent adverse factor for both PFS ($P=0.009$) and OS ($P=0.001$) (Table 5).

The synthesis rate of IgD is very low in patients bearing the IgD subtype, which often leads to missed diagnosis [2]. Among the 216 MM patients, 13 had IgD subtype (6%). This proportion was similar to another report in China (5.4%) [8] but was slightly higher than that observed in western countries (1%–2%) [2]. Nevertheles, the proportion of IgD subtype may still be underestimated, therefore, identifying and understanding this disease is extremely essential.

Table 3 Abnormal cytogenetic characteristics in 198 case of MM patients

| Variable | IgD subtype [cases (%)] | Non-IgD subtypes [cases (%)] | $P$ value |
|----------|------------------------|-----------------------------|-----------|
| Total    | 12                     | 186                         |           |
| 13 deletion | 4 (33.3)               | 59 (31.7)                  | 0.907     |
| 1q21 amplification | 9 (75.0)               | 75 (40.3)                   | 0.018     |
| IGH rearrangement | 6 (50.0)               | 59 (31.7)                   | 0.191     |
| t(4;14) | 3 (25.0)               | 31 (16.7)                   | 0.729     |
| t(11;14) | 1 (8.0)                | 25 (13.4)                   | 0.866     |
| t(14;16) | 2 (17.0)               | 3 (1.6)                     | 0.023     |
| p53 deletion | 0 (0)                  | 7 (3.8)                     | 1.000     |
| Hyperdiploid | 4 (33.3)               | 71 (38.2)                   | 0.948     |

Table 4 Treatment and survival of the 13 patients with IgD subtype MM

| Patient no. | ISS stage | Sex | Age (years) | Introduction therapy/ cycles | Response | Therapy after PD/ cycles | Survival status | PFS (months) | OS (months) |
|-------------|-----------|-----|-------------|------------------------------|----------|--------------------------|----------------|-------------|-------------|
| 1           | III       | Male | 51          | CTD/5                        | CR       | RAD/6                    | Alive          | 6.0         | 17.6        |
| 2           | III       | Female | 53         | CTD/7                        | PR       | RD/8                     | Alive          | 8.0         | 19.5        |
| 3           | III       | Male | 64          | VCD/1                        | PD       | NA                       | Dead           | 0.7         | 0.9         |
| 4           | III       | Male | 48          | VTD/8                        | PR       | RCD                      | Dead           | 26.2        | 44.3        |
| 5           | III       | Female | 59         | VTD/2                        | SD       | NA                       | Dead           | 5.1         | 5.7         |
| 6           | III       | Male | 44          | VCD/9                        | CR       | TAD/6 + RAD/6             | Alive          | 42.3        | 47.0        |
| 7           | III       | Female | 49         | VTD/9                        | CR       | RAD/10                   | Dead           | 28.0        | 42.6        |
| 8           | III       | Male | 52          | VCD/9                        | VGPR     | RD/6                     | Dead           | 8.5         | 13.0        |
| 9           | III       | Male | 45          | VCD/2                        | CR       | CTD/8                    | Alive          | 2.4         | 9.2         |
| 10          | III       | Male | 59          | VD/4                         | PR       | VCD/5                    | Dead           | 16.7        | 16.7        |
| 11          | III       | Male | 51          | CTD/5                        | PR       | RAD/3                    | Dead           | 10.0        | 6.6         |
| 12          | III       | Female | 56         | VCD/4 + ASCT                 | VGPR     | CTD/4                    | Dead           | 18.7        | 22.9        |
| 13          | III       | Female | 66         | VD/4                         | VGPR     | RD/6                     | Dead           | 48.0        | 66.0        |

IgD immunoglobulin D, IGH immunoglobulin heavy chain gene
with higher \( \beta_2 \)-M, extramedullary involvement, secondary systemic amyloidosis, a \( \lambda \) light chain bias (IgD myeloma is characterized by the presence of a predominance of \( \lambda \) over K light chain type), renal failure, and short survival [3]. The clinical characteristics of our patients were similar to the results of the above-mentioned studies.

In addition, we interestingly found that patients with the IgD subtype demonstrated significant sFLC ratio abnormalities at baseline and during disease relapse, especially in the 46.2% of patients with disease relapse. This finding may be conducive to assess the disease progression and to identify early relapse for timely intervention. Moreover, as compared to the IgD subtype patients with abnormal sFLC ratio, those with normal sFLC ratio had a numerically superior OS (42.56 months vs. 5.7 months, \( P = 0.057 \), Additional file 3: Figure S2). There was noted solely as a tendency, which may have been most likely due to the small cohort size.

High-risk cytogenetic abnormalities in MM patients with IgD subtype have been reported to range from 30 to 50%. In our study, 1q21 amplification was observed in 75% of patients with IgD subtype. It was reported that the overexpression of genes mapping to 1q21 could regulate the growth and resistance of MM to drugs, and result in increasing risk of early death of the patients [10]. Recent research has also found that the adverse effects due to 1q21 amplification on prognosis persisted even after removal of other identified high-risk cytogenetic changes, including p53 deletion, t(4;14), t(14;16), and t(14;20) [11]. Therefore, the association of IgD MM with a high rate of 1q21 amplification might contribute to poor outcomes. Perhaps it could also explain why patients with IgD subtype and non-IgD subtypes had similar response rates, but different duration of response.

Researchers have tried different ways to improve the prognosis of patients with IgD subtype all along. In 2005, Wechalekar et al. [5] suggested that the mean OS of IgD subtype patients could be prolonged after ASCT when compared with chemotherapy (5.1 years vs. 2 years, respectively, \( P = 0.090 \)). In 2014, Zagouri et al. [12] reported a median OS of 51.5 months in 31 IgD subtype patients in Greece, which was the longest survival treated

### Table 5 Multivariate analysis for PFS and OS of 216 patients with multiple myeloma

| Variable                      | PFS HR (95% CI) | P value | OS HR (95% CI) | P value |
|-------------------------------|----------------|---------|----------------|---------|
| LDH > 250 U/L                 | 1.494 (1.020–2.189) | 0.039   | 2.791 (1.692–4.604) | <0.001 |
| ISS stage III                 | 1.298 (1.032–1.633) | 0.026   | 1.533 (1.096–2.145) | 0.013   |
| IgD subtype                   | 2.221 (1.221–4.040) | 0.009   | 3.506 (1.687–7.285) | 0.001   |
| 1q21 amplification            | – (–)           | –       | 1.949 (1.179–3.224) | 0.009   |
| IGH rearrangement             | 1.615 (1.260–2.071) | <0.001  | 1.485 (1.165–1.895) | 0.001   |
| Extramedullary infiltration   | 2.084 (1.421–3.055) | <0.001  | 3.692 (2.199–6.200) | <0.001  |

PFS progression-free survival, OS overall survival, HR hazard ratio, CI confidence interval, LDH lactate dehydrogenase, ISS international staging system, IgD immunoglobulin D, IGH immunoglobulin heavy chain gene
with chemotherapy reported until now. However, in Asia, the data seemed less consistent. In 2008 and 2010, two studies from Korea reported poor outcomes for the IgD subtype patients following ASCT or conventional chemotherapy, with the median OS of 12 and 18.5 months [4, 7]. In 2015, a report from China showed that the median OS and PFS of IgD subtype were 24 and 15.5 months, respectively and no difference in OS was found among the bortezomib-only group, the non-bortezomib group, and the bortezomib + ASCT group [8]. Here, our patients with IgD subtype showed similar median OS (22.9 months) and PFS (10 months) as to these studies from Asia. Though patients with non-IgD subtypes had a favourable median OS of 81.7 months in our study, in the era of novel agents, the survival of patients with IgD subtype still cannot be improved from the new drugs, unlike the non-IgD subtypes. Recently, a case report on a patient with IgD subtype who was refractory to at least 5 different chemotherapy regimens had shown very good partial response to daratumumab (anti-CD38 monoclonal antibody) [13]. We expect that additional agents with novel mechanism including histone deacetylation, target of surface receptors, and chimeric antigen receptor T Cell immunotherapy would improve the survival of IgD subtype patients.

In summary, the IgD subtype was found to be an independent adverse risk factor for prognosis. MM patients with IgD subtype presented with a more aggressive disease course and had shorter survival with chemotherapy as compared to the non-IgD subtypes, even in this era of novel agents. Considering the rarity of this subtype, international collaborative studies are suggested to confirm our findings and further elucidate the underlying mechanisms for developing potent therapeutic approaches.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s40880-019-0395-3.

Additional file 1: Table S1. Univariate analysis for PFS and OS of 216 patients with multiple myeloma.

Additional file 2: Figure S1. Kaplan–Meier overall survival curves of patients with multiple myeloma. a: Survival curves of patients stratified according to β,M ≤ 5.5 mg/L vs. > 5.5 mg/L (P = 0.002); b: Survival of patients according to LDH, ≤ 250U/L vs. > 250U/L (P < 0.001); c: Survival of patients with and without extramedullary infiltration (P < 0.000); d: Survival of patients with and without ISS stage III (P = 0.028); e: Survival of patients with and without 13q deletion (P = 0.003); f: Survival of patients with and without 1q21 amplification (P < 0.000); g: Survival of patients with and without different IGH rearrangement [non-IGH rearrangement vs. t(4;14) vs. t(11;14) vs. t(14;16), P < 0.000]; h: Survival of patients with and without abnormal sFLC ratios (P = 0.035).

Additional file 3: Figure S2. Overall survival in IgD myeloma patients with and without abnormal sFLC ratio.

Abbreviations
ASCT: autologous stem cell transplantation; AL amyloidosis: amyloid light-chain amyloidosis; β,M: high β,M microglobulin; CR: complete response; CI: confidence interval; HR: hazard ratio; IgD/MM: immunoglobulin D multiple myeloma; IGH: immunoglobulin heavy-chain gene; IMiD: immunomodulatory drug; ISS: international staging system; LDH: lactate dehydrogenase; OS: overall survival; PD: progressive disease; PFS: progression-free survival; PR: partial response; sFLC: serum-free light chain; sCR: strict complete response; SD: stable disease; VGPR: very good partial response.

Acknowledgements
We would like to thank all the doctors and nurses of Jinling Hospital, and in particular many colleagues for referring and providing clinical data. We would like to thank all patients participated in this study and who attend our center.

Authors’ contributions
QZ and FL analyzed the data and prepared the paper. YPZ designed the research and checked the data. PS, XGZ, ZMA, XLW, and XG provided the clinical data and were responsible for the data interpretation. JGM, HQL, and JJS confirmed the diagnosis and cytogenetics data and were responsible for reviewing the manuscript. All authors read and approved the final manuscript.

Funding
Not applicable.

Availability of data and materials
The dataset used or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
This study was approved by the Clinical Research Ethics Committee of Jinling Hospital, Nanjing, China. Written informed consent was waived by the ethics committee.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 25 April 2019 Accepted: 6 September 2019

Published online: 27 September 2019

References
1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046–60.
2. Pandey S, Kyle RA. Unusual myelomas: a review of IgD and IgE variants. Oncology. 2013;27(8):798–803.
3. Jancelewicz Z, Takatsuki K, Sugai S, Pruzanski W. IgD multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients. Ann Oncol. 2010;21(2):411–6.
4. Wechalekar A, Amato D, Chen C, Stewart AK, Reece D. IgD multiple myeloma—a clinical profile and outcome with chemotherapy and autologous stem cell transplantation. Ann Hematol. 2005;84(2):115–7.
5. Francesco P, Teresa PM, Diana G, Velia B, Marco M, Valerio DS, et al. IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy. J Exp Clin Cancer Res. 2012;31(1):17.
6. Yong PC, Kim S, Ko OB, Koo JE, Lee D, Sang HP, et al. Poor outcomes for IgD multiple myeloma patients following high-dose melphalan and autologous stem cell transplantation: a single center experience. J Korean Med Sci. 2008;23(5):819.
8. Wang GR, Sun WJ, Chen WM, Huang ZX, Zhang JJ, An N, et al. Immunoglobulin D multiple myeloma: disease profile, therapeutic response, and survival. Acta Haematol. 2016;136(3):140–6.

9. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–20.

10. Zhan F, Colla S, Wu X, Chen B, Stewart JP, Kuehl WM, et al. CKS1B, over-expressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood. 2007;109(11):4995.

11. Boyd KD, Ross FM, Chiecchio L, Dagrada GP, Konn ZJ, Tapper WJ, et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia. 2012;26(2):349–55.

12. Zagouri F, Kastritis E, Symeonidis AS, Giannakoulas N, Katodritou E, Delimpasis S, et al. Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents. Eur J Haematol. 2014;92(4):308–12.

13. Husnain M, Kurtin S, Barkett N, Riaz I, Agarwal A. Refractory IgD multiple myeloma treated with daratumumab: a case report and literature review. Case Rep Oncol Med. 2017;2016(10):2490168.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions